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Introduction
Liver transplantation for hepatocellular carcinoma 
(HCC) was initially performed for lesions that were large 
and bilateral and thus unresectable, but recurrence of 
disease was common and mid-term survival was poor (1). 
Patients with less advanced disease had better mid-term 
survival (2). It was the seminal work by Mazzaferro et al. of 
Milan - hence known as the Milan criteria - that established 
an easy reference for case selection for liver transplantation 
for HCC. The criteria state that an HCC patient is selected 
for transplantation when he or she has either a single lesion 
not larger than 5 cm or two or three lesions not larger than 
3 cm each (3). With the Milan criteria, a 4-year survival 
rate of 85% was achieved. It compares favorably with those 
achieved by transplants performed for other indications 
like liver failure. The Milan criteria have been adopted as a 
standard to justify allocations of deceased donor liver grafts 
from a utilitarian point of view.
Review Article
Selection of patients of hepatocellular carcinoma beyond the 
Milan criteria for liver transplantation
See Ching Chan1,2, Sheung Tat Fan1,2
1State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China; 2Department of Surgery, The University of Hong Kong, 
Hong Kong, China
Corresponding to: Prof. Sheung Tat Fan. 102 Pok Fu Lam Road, Hong Kong, China. Email: stfan@hku.hk.
Abstract: The Milan criteria have been proven to be reliable and easily applicable in selection of patients 
with small unresectable hepatocellular carcinomas for liver transplantation. It has been repeatedly shown 
that patients who met these criteria had a 5-year survival of over 70% after transplantation. Such a result is 
remarkably good for an otherwise incurable malignancy. The main disadvantage of this set of criteria is that 
it is rather restrictive. Following it religiously denies transplantation to many patients who have tumor stage 
slightly more advanced.
There have been many attempts to extend the criteria to include tumors with larger sizes (as in the 
UCSF criteria) or with a larger number (as in the Kyoto criteria). Alpha-fetoprotein and PIVKA-II, two 
biological markers in more aggressive tumors, have also been employed in the selection of patients, and 
biopsies have been used by the University of Toronto to determine tumor aggressiveness before deciding on 
transplantation. Patients with tumors beyond the Milan criteria yet not of a high grade have been accepted 
for transplantation and their survival is comparable to that of transplant recipients who were within the 
Milan criteria. Preoperative dual-tracer (11C-acetate and FDG) positron emission tomography has been 
used to determine tumor grade, and transarterial chemoembolization has been used to downstage tumors, 
rendering them meeting the Milan criteria. Patients with downstaged tumors have excellent survival after 
transplantation. Partial response to chemical treatment is a reflection of less aggressive tumor behavior.
Careful selection of patients beyond the Milan criteria with the aid of serum tumor marker assay, positron 
emission tomography or tumor biopsy allows transplanting more patients without compromising survival. 
The use of liver grafts either from the deceased or from living donors could thus be justified.
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The University of Southern California criteria
Although the Milan criteria provide a reliable and practical 
guideline for selecting HCC patients to undergo liver 
transplantation, they are considered rather restrictive. 
In order to let more HCC patients benefit from liver 
transplantation, Yao studied consecutive transplant 
recipients over a 12-year period and formulated a modest 
expansion of the Milan criteria: solitary HCC ≤6.5 cm, or ≤ 
3 nodules with the largest lesion ≤4.5 cm and a total tumor 
diameter ≤8 cm. With this new set of criteria, a 5-year 
survival rate of 75% was achieved.
For this study, one should note that 76%, 16%, and 
9% of the preoperative tumor staging was accurate, 
underestimated and overestimated respectively (4). It is 
also important to be aware that tumor staging in the study 
by Mazzaferro was done with preoperative computed 
tomography (3). Tested in a series by Schwartz of Mount 
Sinai, the expansion to the UCSF criteria offers the 
potential benefit of transplanting around 10% more patients 
with HCC without compromising survival (5). 
Criteria from Asian centers
The University of Tokyo adopts the 5-5 rule: patients are 
selected for transplantation if they have HCC not larger 
than 5 cm and no more than 5 nodules. With this rule, 
an excellent recurrence-free survival rate of 94% was 
achieved (6). At Asan Medical Center, patients with HCC 
not larger than 5 cm and 6 or fewer nodules without gross 
vascular invasion are eligible for transplantation. A 5-year 
survival rate of 81.6% was achieved (7). 
Kyoto University employed the biological marker PIVKA-
II and further extended the number of HCC to 10 with the 
condition that serum PIVKA-II level must be lower than 
400 mAU/mL. A 5-year survival rate of 86.7% was 
achieved (8). At Kyushu University, a 5-year survival rate 
of 82.7% was achieved in patients with HCC not larger 
than 5 cm and a serum PIVKA-II level not higher than 
300 mAU/mL (9). A study in Japan involving 49 centers and 
653 patients reported that patients who were beyond the Milan 
criteria but had serum alpha-fetoprotein levels not higher 
than 200 ng/mL and serum PIVKA-II levels not higher than 
100 mAU/mL had a disease-free survival rate of 84.3% (10).
The Hangzhou center in China also extended the 
selection criteria and employed biological marker. 
Patients who have HCC larger than 8 cm are eligible for 
transplantation if their serum alpha-fetoprotein level is not 
higher than 400 ng/mL and their tumor biopsy shows only 
grade I or II differentiation. A 5-year survival rate of 72.3% 
was achieved (11) (Table 1).
The Toronto and up-to-7 criteria
A radical extension of inclusion criteria was proposed by the 
University of Toronto on the grounds of the deficiencies of 
the existing guidelines. It is difficult to identify small lesions 
accurately in multifocal HCC. Tumor size measurement 
may not be reproducible. Tumor behavior may not be 
related to tumor size and number. And overstaging (23%) 
or understaging (30%) of disease by imaging happens every 
now and again.
 Table 1 Criteria for liver transplantation for hepatocellular carcinoma at different centers
Criteria Tumor size (cm) Tumor number Remark Overall survival
University of Hong Kong (12) ≤6.5 1 Not tested 3-year 78%
5-year 66%≤4.5 ≤3
Chang Gung Hospital (13) ≤6.5 1 Not tested 3-year 96%
5-year 90%≤4.5 ≤3
Asan Medical Center (7) ≤5 ≤6 Not tested 3-year 88%
 5-year 82%
University of Tokyo (6) ≤5 ≤5 Not tested 3-year 82%
5-year 75%
Kyoto University (14) ≤5 ≤10 PIVKA-II ≤400 mAU/mL 5-year 87%
Kyushu University (9) ≤5 No restriction PIVKA-II <300 mAU/mL 3-year 86%
5-year 83%
Hangzhou (11) <8 in total No restriction If >8 cm, then grade I/II + AFP <400 ng/mL 5-year 72%
DuBay (15) No restriction No restriction Poorly differentiated HCC excluded 5-year 72%
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At the University of Toronto, HCC patients whose 
main lesion biopsy did not show poor differentiation were 
transplanted even if they had disease beyond the Milan 
criteria, and the 5-year survival rate of these patients was 
70% while that of patients within the Milan criteria was 
72% (15) (Table 1).
Tumor biopsy has the potential problem of sampling 
error. For instance, a nodule-in-nodule tumor can have 
different tumor grades (16). It has also been demonstrated 
that even in a single-needle biopsy, adjacent tumor cells can 
be of different degrees of differentiation (17). Nevertheless, 
if transplantation is planned for HCC beyond standard 
criteria, tumor biopsy appears to be a logical approach.
Biological grading of tumors by positron emission 
tomography has been employed to identify patients with 
HCC beyond the Milan criteria. However, comparable 
survival was found between patients beyond and patients 
within the criteria (18). In fact, it has been shown that HCC 
which is highlighted by the tracer FDG is more likely of 
a high grade whereas the tracer 11C-acetate used in dual-
tracer positron emission tomography has a closer affinity 
with low-grade HCC (19). Although high-grade HCC is 
more likely to have microvascular invasion (20), the mere 
demonstration of an HCC being FDG-positive does not 
predict the presence of microvascular invasion (21). 
Nevertheless, microvascular invasion alone does not 
adversely affect patient survival if the HCC is within the up-
to-7 criteria, which were proposed by Mazzaferro et al. on 
a basis of 1556 patients from 36 centers (22,23). When the 
addition of the number of tumors and the size of the largest 
tumor (in centimeter) results in a number not larger than 7, 
the up-to-7 criteria are satisfied. In the study by Mazzaferro 
et al., patients who met the up-to-7 criteria had a 5-year 
survival rate of 71.2% (22). 
Downstaging
Instead of extending the selection criteria, downstaging 
the HCC to within the Milan criteria is another logical 
way to transplant more patients. In a study, excellent 
survival was achieved after the tumors were downstaged 
with transarterial embolization or percutaneous ethanol 
injection. Of the eight patients successfully downstaged, 
only one patient had recurrence of HCC after liver 
transplantation (13). 
In another study, three groups of patients were selected 
for downstaging using transarterial chemoembolization or 
laparoscopic radiofrequency ablation. The three groups 
were (I) patients with a single tumor ≤8 cm, (II) patients 
with 2 or 3 tumors each ≤5 cm and totally ≤8 cm, and (III) 
patients with 4 or 5 tumors each ≤3 cm and totally ≤8 cm. 
An observation period of three months after downstaging 
was mandatory. Patients were offered transplantation if 
they showed no tumor progression during the observation 
period. Forty-three of the 61 patients (70.5%) were 
successfully downstaged. The 35 patients who were 
transplanted had a 4-year survival rate of 92.1% (24). 
This “ablate and wait” strategy allows the tumor biology 
to be manifested more clearly, enabling justification of 
transplantation and vice versa. HCC progression after 
ablation is a sign of aggressive tumor behavior which warns 
against liver transplantation (25). 
Salvage liver transplantation
It has also been proposed that patients with HCC beyond 
the Milan criteria can be treated initially with hepatectomy 
and be salvaged with liver transplantation if their recurrent 
HCC is within the Milan criteria and the tumors are less 
aggressive (26). Asan Medical Center showed that salvage 
liver transplantation for recurrent HCC within the Milan 
criteria had outcome comparable with that of primary 
liver transplantation (27). All too often recurrence of large 
and multiple HCC after hepatic resection is extrahepatic 
and contraindicates salvage transplantation. It has been 
found that around one-fifth of patients have extrahepatic 
recurrence and detection of recurrence may not be early 
enough. Moreover, salvage transplantation is applicable to 
less than one-third of the cases (28). Thus, Asan Medical 
Center proposed primary transplantation for HCC that 
comprises 3 or more lesions and meets the selection criteria 
(number ≤6 and size ≤5 cm) (7,29). 
Tumor stage and characteristics at the time of salvage 
transplantation are closely related to tumor recurrence, 
especially recurrence that occurs soon after operation. HCC 
with a large size, multiple lesions, poor differentiation, 
vascular invasion and early recurrence warns against salvage 
transplantation.
Discussion
Hepatitis B is endemic in many parts of Asia, with a carrier 
rate of over 10% in the population. As hepatitis B virus is an 
oncologic virus for HCC, the burden of HCC is particularly 
heavy in these regions. Although liver transplantation 
is an effective treatment of HCC, the scarcity of livers 
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donated by the deceased, which is particularly severe in 
Asia, has limited its application. As a result, living donor 
liver transplantation has become the alternative to deceased 
donor liver transplantation. In order to maintain a high ratio 
of recipient benefit to donor risk, recipient survival has to 
be high in living donor liver transplantation. Patients with 
unresectable HCC have extremely poor survival. However, 
a 50% post-transplant of rate is definitely better than an 
incurable disease. Given the inevitable donor risk, recipient 
survival of living donor liver transplantation for non-HCC 
conditions should be somewhere around 80%. However, 
donor enthusiasm, supply of deceased donor livers and 
disease burden of the region may allow some flexibility 
in accepting a lower recipient survival rate. But flexibility 
should not be abused routinely, otherwise poor recipient 
survival would result. It should be borne in mind that poor 
recipient survival means that a considerable proportion of 
liver donations are vain efforts.
Close auditing of donor and recipient outcomes time 
after time enables modification of recipient selection 
protocols, thereby minimizing the chance of transplanting 
patients with poor outlook. While published references 
on upper limits of tumor size and number, tumor marker 
level and tumor grade (Table 1) are useful in guiding 
clinical decision, we must also exercise judgment based 
on experience and scientific knowledge. A tumor with a 
pseudocapsule but without microvascular invasion has a 
small chance of extrahepatic dissemination even if it is large. 
Gentle handling of the tumor-housing native liver during 
recipient hepatectomy prevents spillage of tumor cells into 
the circulation and is particularly crucial when treating 
tumors with size beyond standard criteria. 
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